Advertisement 454 Life Sciences and IDT sign agreement for primer design and supply - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

454 Life Sciences and IDT sign agreement for primer design and supply

454 Life Sciences, a Roche company, and Integrated DNA Technologies, a supplier of custom nucleic acids, have signed an exclusive co-promotional agreement wherein IDT will design, synthesize, and purify the fusion primers required for certain 454 sequencing applications.

These applications include ultra-deep amplicon sequencing for detection of low-frequency mutations in disease associated genes, and the comprehensive identification and quantification of common and rare variants within a population.

The partnership offers Genome Sequencer FLX system users a convenient solution for primer creation, streamlining workflow and relieving bioinformatics burdens, the two companies said.

Integrated DNA Technologies’s (IDT) online fusion primer design tool uses a gen-specific data base number or a supplied reference sequence to build appropriate 454 FusionPrimers for targeted DNA regions, including individual exons or all exons from one or more genes.

Chris McLeod, CEO of 454 Life Sciences, said: “We are pleased to leverage IDT’s significant experience in primer design and construction to offer our customers a one-stop solution for all their targeted resequencing projects. By shifting the task of primer design to IDT’s online tool, researchers can now focus their efforts on making discoveries.”